Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study

dc.contributor.author	Ross DM
dc.contributor.author	Masszi, Tamás
dc.contributor.author	Gómez Casares MT
dc.contributor.author	Hellmann A
dc.contributor.author	Stentoft J
dc.contributor.author	Conneally E
dc.contributor.author	Garcia-Gutierrez V
dc.contributor.author	Gattermann N
dc.contributor.author	Le Coutre PD
dc.contributor.author	Martino B
dc.contributor.author	Saussele S
dc.contributor.author	Giles FJ
dc.contributor.author	Radich JP
dc.contributor.author	Saglio G
dc.contributor.author	Deng W
dc.contributor.author	Krunic N
dc.contributor.author	Bédoucha V
dc.contributor.author	Gopalakrishna P
dc.contributor.author	Hochhaus A
dc.date.accessioned	2018-10-16T07:40:09Z
dc.date.available	2018-10-16T07:40:09Z
dc.date.issued	2018
dc.identifier	85042212112
dc.identifier.citation	pagination=945-954; journalVolume=144; journalIssueNumber=5; journalTitle=JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY;
dc.identifier.uri	http://repo.lib.semmelweis.hu//handle/123456789/6314
dc.identifier.uri	doi:10.1007/s00432-018-2604-x
dc.relation.ispartof	urn:issn:0171-5216
dc.title	Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study
dc.type	Journal Article
dc.date.updated	2018-09-01T10:18:27Z
dc.language.rfc3066	en
dc.identifier.mtmt	3340901
dc.identifier.wos	WOS:000430975800015
dc.identifier.pubmed	29468438